Cargando…
Personalized Medicine’s Bottleneck: Diagnostic Test Evidence and Reimbursement
Background: Personalized medicine is gradually emerging as a transformative field. Thus far, seven co-developed drug-diagnostic combinations have been approved and several dozen post-hoc drug-diagnostic combinations (diagnostic approved after the drug). However, barriers remain, particularly with re...
Autores principales: | Cohen, Joshua P., Felix, Abigail E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263971/ https://www.ncbi.nlm.nih.gov/pubmed/25563222 http://dx.doi.org/10.3390/jpm4020163 |
Ejemplares similares
-
The Australian experiment: the use of evidence based medicine for the reimbursement of surgical and diagnostic procedures (1998–2004)
por: O'Malley, Sue P
Publicado: (2006) -
Application of Economic Evaluation to Assess Feasibility for Reimbursement of Genomic Testing as Part of Personalized Medicine Interventions
por: Simeonidis, Stavros, et al.
Publicado: (2019) -
Paving the road to personalized medicine: recommendations on regulatory, intellectual property and reimbursement challenges
por: Knowles, Lori, et al.
Publicado: (2017) -
Stratified Medicine and Reimbursement Issues
por: Fugel, Hans-Joerg, et al.
Publicado: (2012) -
Medicines Compliance and Reimbursement Level in Portugal
por: Constantino Portela, Maria da Conceição, et al.
Publicado: (2015)